TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RARE

Ultragenyx

Healthcare · Biotechnology

14.50$ +0.1% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Balance Sheet

Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,532 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RARE
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
198 560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
187 450 498 244 522 851 1,295 857 884 732 817 951
24 94 161 100 113 434 714 308 133 214 174 434
187 437 498 244 460 755 1,202 740 748 577 610 693
5.2 13 33 23 44 40 73 122 159
0.0 0.0 0.0 0.8 7.1 12 13 16 27 34 45 52
3.0 7.4 17 22 20 75 74 141 260
0.0 0.0 0.0 44 44 44 44 44 44 44 44 44
0.0 0.0 0.0 142 129 129 131 131 160 166 178 176
13 28 67 107 111 482 605 600 1,193 1,216 1,241 1,605
13 28 60 71 75 103 190 181 261 280 344 384
7.2 9.0 11 12 13 10 81
4.9 2.9 5.4 8.9 12 13 13 17 43 42 39 31
0.0 0.0 0.0 0.0
185 531 474 383 609 654 1,154 923 352 275 255 -80
-139 -285 -531 -833 -1,030 -1,433 -1,620 -2,074 -2,781 -3,388 -3,957 -4,532
29 37 40 42 50 57 61 68 70 74 91 99

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?